Global Hematuria Treatment Market Revenue Grows at a CAGR of 3.18%

Introduction

Straits Research released its highly anticipated report, “Global Hematuria Treatment Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 1.28 billion in 2025 and is anticipated to grow to USD 1.69 billion by 2034, growing at a CAGR of 3.18% from 2026-2034.

Market Dynamics

The global hematuria treatment market is poised for steady growth, driven primarily by the rising incidence of underlying urological conditions such as urinary tract infections, kidney stones, benign prostatic hyperplasia and malignancies affecting the kidneys and bladder. Increasing awareness among patients regarding the importance of early detection and timely medical intervention has further accelerated demand for diagnostic procedures and treatment modalities. Moreover, advancements in imaging technologies, minimally invasive procedures and pharmacological therapies have significantly improved clinical outcomes, making hematuria management more effective and accessible. The growing geriatric population, which is more prone to urological complications, also contributes to sustained market expansion.

However, the market faces restraints that may hinder its full growth potential. One of the key challenges includes the high cost associated with advanced diagnostic tools such as CT urography, cystoscopy and MRI scans, which may limit access in low and middle income regions. Additionally, the asymptomatic nature of microscopic hematuria often leads to delayed diagnosis, resulting in lower treatment uptake. Limited healthcare infrastructure in developing nations further affects timely detection and management.

Despite these challenges, the hematuria treatment market offers significant opportunities. Continued research into noninvasive diagnostic tools and biomarker based screening can help streamline diagnosis, reduce costs and expand access. Pharmaceutical innovation, particularly in targeted therapies for conditions like IgA nephropathy and bladder cancer, also presents strong growth potential. Furthermore, the increasing shift toward telemedicine and digital health platforms offers new avenues for patient monitoring, follow up care and early symptom reporting, positioning the market for long-term advancement.

Key Highlights

• Based on Type, the gross hematuria segment is anticipated to register the fastest CAGR of 4.12% during the forecast period.
• Based on the Indication, the benign prostate enlargement dominated the market with a revenue share of 36.25% in 2025.
• Based on Treatment Type, the therapies segment is anticipated to register the fastest CAGR of 4.45%.
• Based on the Distribution Channel, the Hospital Pharmacy segment dominated the market with 42.32%.
• North America held a dominant share of the global market, accounting for 43.24% share in 2025.

Competitive Players

1. Sanofi
2. Teva Pharmaceutical Industries Ltd
3. Astellas Pharma Inc.
4. Lupin Pharma Canada Ltd.
5. Vera Therapeutics
6. Ferring
7. RemeGen Co., Ltd.
8. Novartis AG
9. Abbott
10. Reddy's Laboratories Ltd.
11. Johnson & Johnson
12. Pfizer Inc. 
13. Others

Recent Developments

October 2024: Vera Therapeutics announced data from its ORIGIN Phase 2b trial, stating that atacicept had stabilized kidney function and had significantly improved hematuria in patients with immunoglobulin A nephropathy (IgAN) over a 96-week period.

Segmentation

1. Type (2026-2034)
   1. Gross Hematuria
   2. Microscopic Hematuria
2. By Indication (2026-2034)
   1. UTI
   2. Kidney Stones
   3. Tumor in kidney or bladder
   4. Benign prostate enlargement
3. Treatment Type (2026-2034)
   1. Drugs
      1. Antibiotics
      2. Diuretics
      3. Alpha-blockers
      4. Others
   2. Therapies
      1. Pharmacotherapy
      2. Procedural / Interventional Therapies
      3. Adjunctive / Supportive Therapies
4. Distribution Channel (2026-2034)
   1. Hospital Pharmacy
   2. Online Pharmacy
   3. Retail Pharmacy